Serial Assessment of Cardiac Function during and following Mitoxantrone Infusion in 30 Consecutive Patients with Multiple Sclerosis

Abstract EN

Immunosuppressive therapy is an established therapeutic option in patients suffering from multiple sclerosis (MS).

In an open nonrandomized study we serially assessed cardiac function in 30 consecutive patients with MS before, during, and after mitoxantrone therapy.

Mitoxantrone (12 mg/m2) was administered intravenously at 3-month intervals.

Before each infusion, cardiac function was assessed by history taking, resting electrocardiogram, and echocardiography.

Whereas no patient experienced clinical signs of heart failure, left ventricular pump function decreased continuously during mitoxantrone therapy and did not recover after cessation.

The presented data suggest a dose-dependent and long-lasting toxic cardiac effect of low-dose mitoxantrone therapy in MS.